The BHIVES Collaborative: Organization and Evaluation of a Multisite Demonstration of Integrated Buprenorphine/Naloxone and HIV Treatment
Authors:
- Linda WeissLWLinda Weiss
- James E EganJEJames E Egan
- Michael BotskoMBMichael Botsko
- Julie NetherlandJNJulie Netherland
- David A FiellinDFDavid A Fiellin
- Ruth FinkelsteinRFRuth Finkelstein
- 1 March 2011
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 56 (Supplement) , S7-S13
Abstract
Substance abuse is associated with poor medical and quality-of-life outcomes among HIV-infected individuals. Although drug treatment may reduce these negative consequences, for many patients, options are limited. Buprenorphine/naloxone, an opioid agonist treatment that can be prescribed in the United States in office-based settings, can be used to expand treatment capacity and integrate substance abuse services into HIV care. Recognizing this potential, the US Health Resources and Services Administration funded the development and implementation of demonstration projects that integrated HIV care and buprenorphine/naloxone treatment at 10 sites across the country. An Evaluation and Technical Assistance Center provided programmatic and clinical support as well as oversight for an evaluation that examined the processes for and outcomes of integrated care. The evaluation included patient-level self-report and chart abstractions as well as provider and site level data collected through surveys and in-depth interviews. Although multisite demonstrations pose implementation and evaluation challenges, our experience demonstrates that these can, in part, be addressed through ongoing communication and technical assistance as well as a comprehensive evaluation design that incorporates multiple research methods and data sources. Although limitations to evaluation findings persist, they may be balanced by the scope and "real-world" context of the initiative.Keywords
This publication has 47 references indexed in Scilit:
- Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of BuprenorphineJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site EvaluationJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- The Impact of Cocaine Use on Outcomes in HIV-Infected Patients Receiving Buprenorphine/NaloxoneJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Risk Factors Influencing Antibody Responses to Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Antigens in Patients Under Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Male Antenatal Attendance and HIV Testing Are Associated With Decreased Infant HIV Infection and Increased HIV-Free SurvivalJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Factors affecting willingness to provide buprenorphine treatmentJournal of Substance Abuse Treatment, 2009
- Health-Related Quality of Life in HIV-Infected Patients: The Role of Substance UseAIDS Patient Care and STDs, 2008
- Attitudes Toward Buprenorphine and Methadone Among Opioid‐Dependent IndividualsThe American Journal on Addictions, 2008
- Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and NaloxoneNew England Journal of Medicine, 2003